1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

ACC 2015: Brilinta, PCSK9, andexanet alfa, ETC-1002 sound bites feed stock gains

 
• By Mandy Jackson

Stock price gains for AstraZeneca, Amgen, Regeneron Pharmaceuticals, Portola Pharmaceuticals and Esperion Therapeutics showed that there were no biopharma losers based on data presented during the American College of Cardiology (ACC) Scientific Session & Expo despite unanswered questions about therapies in development.

Stock price gains for AstraZeneca, Amgen, Regeneron Pharmaceuticals, Portola Pharmaceuticals and Esperion Therapeutics showed that there were no biopharma losers based on data presented during the American College of Cardiology (ACC) Scientific Session & Expo despite unanswered questions about therapies in development.

Clinical trial investigators, cardiologists and analysts had a final chance to sound off on the companies' ACC data presentations on 16 March, the final day of the meeting, which began on 14 March in San Diego

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Merck & Co. CMO Eliav Barr Assures On Pipeline As Keytruda LOE Looms Large

 
• By Jessica Merrill

Chief medical officer Eliav Barr, responsible for overseeing clinical development, talked to Scrip in an interview at Merck’s headquarters about the company’s pipeline diversification.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

 
• By Dexter Jie Yan

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.